Hemab Therapeutics Holdings (COAG) Stock Forecast: StockMap's 2-Week Call
COAG stock forecast: StockMap's model leans Underperform on Hemab Therapeutics Holdings for the two weeks after the Nov 19 close, toward COAG trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 4 of 6 two-week windows on COAG since Aug 21; by chance, a call on the same dates was right 59% of the time.
Hemab Therapeutics Holdings last closed at $39.86, +1.81% on the session.
Against the IVW growth benchmark the position is +4.14% over the forecast window.
Hemab Therapeutics Holdings' market cap is $1.86B as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -24 (too close to call).
Where COAG sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 3 bullish and 12 bearish.
Agreement across those insights is 80%.
44 daily calls for COAG so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Hemab Therapeutics Holdings in the 14th percentile on return on equity, where 100 is best.
Hemab Therapeutics Holdings is classified under Health Care / Biotechnology.
StockMap tracks Hemab Therapeutics Holdings as the 91st largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Hemab Therapeutics Holdings ranks 182nd of 394 in the group, against a group median of -0.27.